Prolia (denosumab)

Manufacturer:

Amgen

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

Manufacturer Website

phone:

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of postmenopausal women with osteoporosis at high risk for fracture
to increase bone mass in men with osteoporosis at high risk for fracture
treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

Conditions:

Osteoporosis

Therapeutic Area:

Endocrinology
Geriatrics
Oncology